Microbot Medical (MBOT) Stock: Buy, Sell, or Hold?
MBOT - Microbot Medical, Inc. Common Stock
$1.20
0.00 (0.00%)
▲
5d:
-8.4%
30d:
-18.37%
90d:
-37.17%
WAIT
LOW Confidence
Analysis Updated: Oct 1, 2026 12:00 AM ET
Earnings: Nov 11, 2026
Get Alerted When MBOT Hits Your Target Price
Join 10,000+ traders who never miss a move
You're in! Check your email to confirm and set your target price.
100% Free
No spam, ever
Unsubscribe anytime
Interactive Price Chart (1 Month)
Loading chart...
Loading historical data...
Bottom Line:
📊 MIXED SIGNALS: MBOT shows conflicting indicators. Wait for confirmation before entering.
📊 MIXED SIGNALS: MBOT shows conflicting indicators. Wait for confirmation before entering.
In-depth Analysis How we analyze
Valuation Analysis: MBOT is currently trading at $1.20, which is considered oversold relative to its 30-day fair value range of $1.31 to $1.50. From a valuation perspective, the stock is trading at a discount (Forward PE: -4.0) compared to its historical average (18.5). At these levels, the market is pricing in 0% annual earnings growth. This growth rate appears achievable given the company's track record, suggesting the valuation is rational.
Technical Outlook: Technically, MBOT is in a strong downtrend. The price is currently testing key support at $1.18. A bounce from this level would confirm strength, while a break below could signal further downside.
Market Sentiment: MBOT scores 25/100 on our bottoming-setup gauge. Note this measures entry quality, not trend direction — a low score can mean the chart is extended after a strong run (don't chase) or still falling without stabilization; better entries typically come after a pullback toward the 20-day average. Wall Street analysts see significant upside, with an average price target of $6.33 (+427.8%). Current signals suggest waiting for a better entry point before initiating new positions.
Technical Outlook: Technically, MBOT is in a strong downtrend. The price is currently testing key support at $1.18. A bounce from this level would confirm strength, while a break below could signal further downside.
Market Sentiment: MBOT scores 25/100 on our bottoming-setup gauge. Note this measures entry quality, not trend direction — a low score can mean the chart is extended after a strong run (don't chase) or still falling without stabilization; better entries typically come after a pullback toward the 20-day average. Wall Street analysts see significant upside, with an average price target of $6.33 (+427.8%). Current signals suggest waiting for a better entry point before initiating new positions.
Quick Decision Summary
Current Position
OVERSOLD
Historical Trading Range
$1.31 -
$1.50
Company Quality Score
48/100
(HOLD)
Volume Confirmation
HIGH
Confidence Score
61.9%
All Signals
- BULLISH: Price oversold vs 30-day range
- BEARISH: Weak technical setup (25/100)
- BULLISH: High volume confirmation
- BULLISH: Trading 427.8% below Wall St target ($6.33)
- BULLISH: Market expects only 0% annual growth - appears undervalued
- WARNING: Composite score 48/100 in the bottom quintile — this cohort historically lags the market
Trading Range Analysis
30-Day Trading Range
$1.31 -
$1.50
Current vs Trading Range
OVERSOLD
Support & Resistance Levels
Support Level
$1.18
Resistance Level
$1.43
Current Trend
Strong Downtrend
Technical data as of
Oct 1, 2026
Fundamental Context
Forward P/E (Next Year Est.)
-3.96
Wall Street Target
$6.33
(+427.8%)
PE vs Historical
-4.0 vs 18.5
CHEAP
Share & Embed Analysis
Last updated: October 01, 2026 8:10 PM ET
Data refreshes hourly during market hours. Next update: 9:10 PM
Data refreshes hourly during market hours. Next update: 9:10 PM
🔥 Top Stocks Breaking Out Now
| Ticker | Score | Recommendation | Change % |
|---|
Technical Signals Check
Is MBOT showing a specific setup today?
Insider Activity (6 Months)
0
Buys
0
Sells
0
Net
NEUTRAL
Top Rated Medical Devices Stocks
Top-rated stocks in Medical Devices by analyst ratings.
| Stock | Analyst Consensus | Analyst Target | Tradestie Score |
|---|---|---|---|
|
SYK
Stryker Corporation |
BUY
32 analysts |
$369 | 64 BUY |
|
DXCM
DexCom Inc |
STRONG BUY
27 analysts |
$94 | 48 HOLD |
|
ABT
Abbott Laboratories |
STRONG BUY
27 analysts |
$120 | 49 HOLD |
|
MDT
Medtronic PLC |
BUY
32 analysts |
$105 | 52 HOLD |
|
PODD
Insulet Corporation |
STRONG BUY
24 analysts |
$172 | 44 HOLD |
